U.S. FDA Approves Trodelvy® for First Line Treatment of Metastatic Triple Negative Breast Cancer

The U.S. Food and Drug Administration (FDA) has granted approval for the use of Trodelvy (sacituzumab govitecan-hziy) as a first-line treatment for patients with metastatic triple-negative breast cancer (mTNBC). This decision comes after a Phase 3 clinical trial demonstrated that Trodelvy significantly improved overall survival and progression-free survival in patients with mTNBC compared to the standard chemotherapy regimen of physician's choice. Trodelvy is a monoclonal antibody-drug conjugate that targets the Trop-2 protein, which is overexpressed in many cancer cells, including those of mTNBC. By binding to Trop-2, Trodelvy delivers a potent cytotoxic payload directly to cancer cells, minimizing damage to healthy tissues. This targeted approach has shown promise in treating a range of cancers, and the FDA's approval of Trodelvy for mTNBC represents a major milestone in the ongoing quest to improve outcomes for patients with this aggressive and often treatment-resistant disease.